The Globe and Mail reports in its Tuesday, April 1, edition that Stifel's Martin Landry has reaffirmed his "buy" recommendation for Lassonde Industries. The Globe's David Leeder writes that Mr. Landry's share target soared $18 to $243. Analysts on average target the shares at $240.25. Mr. Landry says in a note: "Lassonde's shares performed well recently, up 17 per cent in the last three months. ... The company is embarking on a large CAPEX cycle, building a new plant in New Jersey and modernizing equipment at various locations. This CAPEX cycle is expected to abate in mid 2026 when the company should reap the benefits, namely increased productivity, increased automation, unlocking of new formats/products and higher employee retention. We believe these should support mid double-digits organic EPS growth, which could be supplemented further with acquisitions. The juice industry is facing structural volume declines but despite these headwinds, Lassonde continues to win market share and growth rapidly. We believe this is underappreciated by investors, which apply a valuation too punitive in our view. One dynamic to monitor is the rapid decline in the price of orange juice concentrate which could be a double-edged sword."